HSP90AA1 and neoplasm: Our new finding will provide valuable information for a specific type of adjuvant combination therapy that combines the inhibitors of Cdc7, HSP90, and/or ATR to block DNA synthesis and exploit defects in DNA repair/checkpoint of tumor cells73.